The COBRE in Lipidomics continues to evolve from basic science studies to animal models and now to translational research. This evolution requires continued advances in basic research, for example, in technology and ability to develop biomarkers. It also requires attracting translational scientists to Lipidomics and/or enabling Lipidomics investigators to conduct translational research through retooling, collaborating to move their investigations from the bench toward clinical application. The Center in Lipidomics and Pathobiology at MUSC builds on substantial accomplishments during the first two phases of the COBRE, including mentoring of 19 targeted junior faculty investigators and participation by ~30 MUSC research faculty in COBRE activities. The COBRE has also been very successful in recruiting minorities and women as target faculty. Many of these successes were enabled through the granting of Pilot Projects to promising investigators. Therefore, the overall goal of this program is to continue the significant momentum we have gained from the previous funding cycles by providing and prioritizing short-term funding for translational and other pilot studies designed to determine expeditiously whether a novel idea or technology has sufficient merit and feasibility to move forward and become the basis of a competitive NIH research project grant application. To this end, we will build on and modify informatics tools and web resources developed and maintained by the South Carolina Clinical and Translational Institute (SCTR) that serve as CTSA-supported infrastructure to develop a platform for electronic submission and review of applications and progress reports for COBRE Pilot Projects Programs. A request for applications (RFA) will be advertised annually. Pilot project investigators may request up to $50,000/yr (up to a total of $100,000 direct costs) for a maximum of two years (24 months). Progress reports will be required at 6-month Intervals with a final report at the end of the designated project period. Second-year support, if requested, will be contingent on productivity. The goals of this Pilot Projects Program will be successfully met by: Increasing the number and competitiveness of translationally based publications and grant proposals in the field of Lipidomics and Pathobiology submitted to NIH and other biomedical research sponsors;strengthening the resources and competitiveness of MUSC to conduct basic, translational and clinical research in the field of Lipidomics and Pathobiology;and consolidating the stature of our Center in Lipidomics and Pathobiology as a nationally and internationally recognized, unique center of excellence in basic and translational studies In Lipidomics and Pathobiology.
This proposal is to support several unique core resources that significantly enhance research on novel bioactive lipids that are involved in many important diseases including cancer, neurodegeneration, diabetes and cardiovascular disease. Moreover, the research has significant impact on drug discovery and innovative biomedical industry that will benefit the economy of SC.
|Spassieva, Stefka D; Ji, Xiaojie; Liu, Ye et al. (2016) Ectopic expression of ceramide synthase 2 in neurons suppresses neurodegeneration induced by ceramide synthase 1 deficiency. Proc Natl Acad Sci U S A 113:5928-33|
|Dany, Mohammed; Gencer, Salih; Nganga, Rose et al. (2016) Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML. Blood 128:1944-1958|
|Yu, H; Sun, C; Argraves, K M (2016) Periodontal inflammation and alveolar bone loss induced by Aggregatibacter actinomycetemcomitans is attenuated in sphingosine kinase 1-deficient mice. J Periodontal Res 51:38-49|
|Podbielska, Maria; Szulc, ZdzisÅ‚aw M; Kurowska, Ewa et al. (2016) Cytokine-induced release of ceramide-enriched exosomes as a mediator of cell death signaling in an oligodendroglioma cell line. J Lipid Res 57:2028-2039|
|Novgorodov, Sergei A; Riley, Christopher L; Keffler, Jarryd A et al. (2016) SIRT3 Deacetylates Ceramide Synthases: IMPLICATIONS FOR MITOCHONDRIAL DYSFUNCTION AND BRAIN INJURY. J Biol Chem 291:1957-73|
|Yu, Hong; Herbert, Bethany A; Valerio, Michael et al. (2015) FTY720 inhibited proinflammatory cytokine release and osteoclastogenesis induced by Aggregatibacter actinomycetemcomitans. Lipids Health Dis 14:66|
|Venant, Heather; Rahmaniyan, Mehrdad; Jones, E Ellen et al. (2015) The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo. Mol Cancer Ther 14:2744-52|
|Geng, Tuoyu; Sutter, Alton; Harland, Michael D et al. (2015) SphK1 mediates hepatic inflammation in a mouse model of NASH induced by high saturated fat feeding and initiates proinflammatory signaling in hepatocytes. J Lipid Res 56:2359-71|
|Novgorodov, Sergei A; Riley, Christopher L; Yu, Jin et al. (2014) Essential roles of neutral ceramidase and sphingosine in mitochondrial dysfunction due to traumatic brain injury. J Biol Chem 289:13142-54|
|Snider, Ashley J (2013) Sphingosine kinase and sphingosine-1-phosphate: regulators in autoimmune and inflammatory disease. Int J Clin Rheumtol 8:|